- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-3305
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Schistosomiasis vaccines: where do we stand? ; volume:9 ; number:1 ; day:30 ; month:9 ; year:2016 ; pages:1-15 ; date:12.2016
Parasites & vectors ; 9, Heft 1 (30.9.2016), 1-15, 12.2016
- Creator
-
Tebeje, Biniam Mathewos
- Contributor
-
Harvie, Marina
You, Hong
Loukas, Alex
McManus, Donald P.
SpringerLink (Online service)
- DOI
-
10.1186/s13071-016-1799-4
- URN
-
urn:nbn:de:1111-20161101650
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:53 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Tebeje, Biniam Mathewos
- Harvie, Marina
- You, Hong
- Loukas, Alex
- McManus, Donald P.
- SpringerLink (Online service)
Other Objects (12)
Scabies vaccines: where we stand and challenges ahead
ColVI myopathies: where do we stand, where do we go?
Toxoplasmosis vaccines: what we have and where to go?
P17-25. A model for coverage of T-cell HIV vaccines: where are we and where do we need to be?
Organizational learning: Where do we stand? Where do we want to go?
Organizational learning: Where do we stand? Where do we want to go?
Organizational learning: Where do we stand? Where do we want to go?
NISQ computing: where are we and where do we go?
Future perspectives on swine viral vaccines: where are we headed?
Neurological and neuropsychological adverse effects of SARS-CoV-2 vaccines – where do we stand?
Nanoparticles in the environment: where do we come from, where do we go to?
EU-China trade relations : Where do we stand, where should we go?
Scabies vaccines: where we stand and challenges ahead
ColVI myopathies: where do we stand, where do we go?
Toxoplasmosis vaccines: what we have and where to go?
P17-25. A model for coverage of T-cell HIV vaccines: where are we and where do we need to be?
Organizational learning: Where do we stand? Where do we want to go?
Organizational learning: Where do we stand? Where do we want to go?
Organizational learning: Where do we stand? Where do we want to go?
NISQ computing: where are we and where do we go?
Future perspectives on swine viral vaccines: where are we headed?
Neurological and neuropsychological adverse effects of SARS-CoV-2 vaccines – where do we stand?
Nanoparticles in the environment: where do we come from, where do we go to?
EU-China trade relations : Where do we stand, where should we go?
Scabies vaccines: where we stand and challenges ahead
ColVI myopathies: where do we stand, where do we go?
Toxoplasmosis vaccines: what we have and where to go?
P17-25. A model for coverage of T-cell HIV vaccines: where are we and where do we need to be?
Organizational learning: Where do we stand? Where do we want to go?
Organizational learning: Where do we stand? Where do we want to go?
Organizational learning: Where do we stand? Where do we want to go?
NISQ computing: where are we and where do we go?
Future perspectives on swine viral vaccines: where are we headed?
Neurological and neuropsychological adverse effects of SARS-CoV-2 vaccines – where do we stand?
Nanoparticles in the environment: where do we come from, where do we go to?